These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32508358)

  • 21. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.
    McCoy K; Hamilton S; Johnson C
    Chest; 1996 Oct; 110(4):889-95. PubMed ID: 8874241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nasally inhaled dornase alfa in the postoperative management of chronic sinusitis due to cystic fibrosis.
    Raynor EM; Butler A; Guill M; Bent JP
    Arch Otolaryngol Head Neck Surg; 2000 May; 126(5):581-3. PubMed ID: 10807324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Respiratory evolution of patient with mucoviscidosis treated with mucolytic agents plus dornase alfa].
    Derelle J; Bertolo-Houriez E; Marchal F; Weber M; Virion JM; Vidailhet M
    Arch Pediatr; 1998 Apr; 5(4):371-7. PubMed ID: 9759155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4-year period.
    Shah PL; Conway S; Scott SF; Rainisio M; Wildman M; Stableforth D; Hodson ME
    Respiration; 2001; 68(2):160-4. PubMed ID: 11287830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: a double-blind placebo-controlled cross-over trial.
    Mainz JG; Schien C; Schiller I; Schädlich K; Koitschev A; Koitschev C; Riethmüller J; Graepler-Mainka U; Wiedemann B; Beck JF
    J Cyst Fibros; 2014 Jul; 13(4):461-70. PubMed ID: 24594542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
    Brophy GM; Sheehan V; Shapiro MJ; Lottenberg L; Scarlata D; Audhya P;
    Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis.
    Fitzgerald DA; Hilton J; Jepson B; Smith L
    Pediatrics; 2005 Oct; 116(4):e549-54. PubMed ID: 16147970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dornase alfa: a new option in the management of cystic fibrosis.
    Witt DM; Anderson L
    Pharmacotherapy; 1996; 16(1):40-8. PubMed ID: 8700791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.
    Quan JM; Tiddens HA; Sy JP; McKenzie SG; Montgomery MD; Robinson PJ; Wohl ME; Konstan MW;
    J Pediatr; 2001 Dec; 139(6):813-20. PubMed ID: 11743506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is a longer time interval between recombinant human deoxyribonuclease (dornase alfa) and chest physiotherapy better? A multi-center, randomized crossover trial.
    Wilson CJ; Robbins LJ; Murphy JM; Chang AB
    Pediatr Pulmonol; 2007 Dec; 42(12):1110-6. PubMed ID: 17955550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis.
    Nasr SZ; Chou W; Villa KF; Chang E; Broder MS
    J Med Econ; 2013; 16(6):801-8. PubMed ID: 23506540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
    Hodson ME
    Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S70-4. PubMed ID: 7881698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nurse-driven pediatric analgesia and sedation protocol reduces withdrawal symptoms in critically ill medical pediatric patients.
    Neunhoeffer F; Kumpf M; Renk H; Hanelt M; Berneck N; Bosk A; Gerbig I; Heimberg E; Hofbeck M
    Paediatr Anaesth; 2015 Aug; 25(8):786-794. PubMed ID: 25810086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis.
    Amin R; Subbarao P; Lou W; Jabar A; Balkovec S; Jensen R; Kerrigan S; Gustafsson P; Ratjen F
    Eur Respir J; 2011 Apr; 37(4):806-12. PubMed ID: 20693248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dornase alfa (Pulmozyme).
    Wagener JS; Kupfer O
    Curr Opin Pulm Med; 2012 Nov; 18(6):609-14. PubMed ID: 22990660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Dornase Alfa Nebulizer Group.
    Geller DE; Eigen H; Fiel SB; Clark A; Lamarre AP; Johnson CA; Konstan MW
    Pediatr Pulmonol; 1998 Feb; 25(2):83-7. PubMed ID: 9516090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dornase alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis.
    Bryson HM; Sorkin EM
    Drugs; 1994 Dec; 48(6):894-906. PubMed ID: 7533697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nutritional support for critically ill children.
    Joffe A; Anton N; Lequier L; Vandermeer B; Tjosvold L; Larsen B; Hartling L
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD005144. PubMed ID: 27230550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients.
    Sawicki GS; Chou W; Raimundo K; Trzaskoma B; Konstan MW
    J Cyst Fibros; 2015 Nov; 14(6):777-83. PubMed ID: 25921451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of chronic rhinosinusitis with dornase alfa in patients with cystic fibrosis: a systematic review.
    Shah GB; De Keyzer L; Russell JA; Halderman A
    Int Forum Allergy Rhinol; 2018 Jun; 8(6):729-736. PubMed ID: 29323796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.